Mauricio Escobar, MD
Hematology & Oncology · Birmingham, ALNPI 1497998736
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,500 of the $5,556 with a category attached, or 63.0%. 29 manufacturers reported payments, led by Dova Pharmaceuticals at 40.5% of the total. Reporting peaked in 2020 at $2,475 and has fallen 85.3% since, to $363 in 2025. That places this record below the midpoint for hematology & oncology clinicians in AL, where the typical reported total is $7,159.
Across 87 payments — averaging $63.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dova Pharmaceuticals$2K
- Dendreon Pharmaceuticals LLC$1K
- Novartis$280
- Pfizer$167
- Lilly USA, LLC$154
- Merck$150
- plus $1K from 23 others
Across 18 payments — averaging $24,954 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$353K
- Merck$96K
What the payments were for
- Consulting fees$3,50063%
- Food & beverage$1,99736%
- Education$591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dova Pharmaceuticals | 1 | $2,250 |
| Dendreon Pharmaceuticals LLC | 4 | $1,443 |
| Novartis | 13 | $280 |
| Pfizer | 9 | $167 |
| Lilly USA, LLC | 7 | $154 |
| Merck | 9 | $150 |
| AstraZeneca(2 entities) | 3 | $143 |
| Pharmacosmos Therapeutics Inc. | 1 | $130 |
| Johnson & Johnson | 6 | $118 |
| Daiichi Sankyo Inc. | 2 | $86 |
| E.r. Squibb & Sons, L.L.C. | 3 | $76 |
| Incyte Corporation | 4 | $63 |
| Stemline Therapeutics Inc. | 2 | $41 |
| Tempus AI, Inc | 2 | $40 |
| AbbVie | 2 | $39 |
| Bristol Myers Squibb | 2 | $39 |
| Tersera Therapeutics LLC | 1 | $37 |
| Rigel Pharmaceuticals, Inc. | 2 | $36 |
| Amgen | 2 | $34 |
| Genentech USA, Inc. | 2 | $32 |
| Gilead | 2 | $31 |
| Adaptive Biotechnologies Corporation | 1 | $28 |
| Sanofi | 1 | $25 |
| Astellas Pharma US Inc | 1 | $21 |
| Bayer | 1 | $20 |
| Karyopharm Therapeutics Inc. | 1 | $20 |
| Masimo Corporation | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DOPTELET$2,250
- PROVENGE$1,398
- Monoferric$130
How this compares
$5,556 in reported general payments places this provider in the 40th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 23 | $351,215 |
| EliquisApixaban | 25 | $26,277 |
| XareltoRivaroxaban | 33 | $15,773 |
| Exemestane | 26 | $3,611 |
| Letrozole | 170 | $3,579 |
| Anastrozole | 38 | $534 |
| Tamoxifen Citrate | 16 | $471 |
| LoperamideLoperamide Hcl | 17 | $336 |
| Hydroxyurea | 18 | $250 |
| Esomeprazole Magnesium | 12 | $196 |
| Omeprazole | 11 | $117 |
| Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12) | 11 | $19 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $154 | $351,21523 claims |
| PfizerEliquis | $167 | $26,27725 claims |
| Johnson & JohnsonXarelto | $118 | $15,77333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Birmingham
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
- Rudolph NavariBirmingham$254K
- Mayur NarkhedeBirmingham$193K
- Midhun MallaBirmingham$144K
- Robert ConryBirmingham$143K
- David MooneyBirmingham$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.